Guo Wei

Prof. Guo Wei


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2019 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
LWLili Wang
Lili Wang
GYGaofei Yin
Gaofei Yin
YGYing Guo
Ying Guo
YZYaqi Zhao
Yaqi Zhao
MZMeng Zhao
Meng Zhao
ZHZhigang Huang
Zhigang Huang
In this study, a next-generation sequencing strategy on 16S rRNA gene was employed to analyze 70 oral samples from 32 patients with throat cancer, 9 patients with vocal cord polyp and 29 healthy individuals (normal controls). Using this strategy, we demonstrated for the first time that the salivary microbiota of cancer patients were significantly different from those of patients with polyp and healthy individuals. We observed that the beta diversity of the cancer group was divergent from both the normal and polyp groups while alpha-diversity indices such as the Chao1 estimator (P = 8.1e-05), Simpson (P = 0.0045) and Shannon (P = 0.0071) were significantly reduced in cancer patients compared with patients containing polyp and normal healthy individuals. LDA and Kruskal-Wallis test analyses and real-time qPCR verification test revealed that genera Aggregatibacter, Pseudomonas, Bacteroides and Ruminiclostridium were significantly enriched in the throat cancer group compared with the vocal cord polyp and normal control group (score value > 2). Finally, diagnostic models based on putatively important constituent bacteria were constructed with 87.5% accuracy (AUC = 0.875, 95% CI: 0.695–1). In summary, in this study we characterized for the first time the oral microbiota of throat cancer patients without smoking history. We speculate that these results will help in the pathogenic mechanism and early diagnosis of throat cancer.

5 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
GYGaofei Yin
Gaofei Yin
GWGuo Wei
Guo Wei
Xiaohong CHENXiaohong CHEN
Xiaohong CHEN
YZYang Zhang
Yang Zhang
ZHZhigang Huang
Zhigang Huang
Head and neck mucosal melanoma is one of the most common types of melanoma in China, but the prognosis is worse than other types, and there is no effective treatment plan to improve patient survival. This study analyzes the efficacy of hypofractionation radiotherapy combined with PD-1 inhibitor in the treatment of head and neck mucosal melanoma, as well as its impact on the tumor immune microenvironment. NPSG mice were used to construct a humanized bilateral lesion tumor model of the humanized immune system. The models were divided into an RT (8 Gy)+anti PD-1 group, an RT (2 GyX4)+anti PD-1 group, an Anti PD-1 group, an RT (8 Gy) group, and a blank group. Differences in efficacy and immune cells in blood, lymph nodes, and tumor tissues were compared between different treatment groups. The treatment effect of RT (8 Gy)+anti PD-1 was better than the other groups with a tumor growth inhibition value (TGI) over 60%. Significant recruitment and activation of CD8+T cells were found in the blood, lymph nodes, and tumor tissues and significantly inhibited the level of PD-1+CD8+T cells in the group of RT (8 Gy)+anti PD-1. This study confirmed the efficacy of hypofractionation radiotherapy combined with PD-1 inhibitors, which can inhibit tumor growth and produce distant effects. The appearance of a distant effect is related to the enhancement in the number and activity of CD8+T cells in the local tumor and peripheral blood and lymph nodes. This study confirms the therapeutic and immune regulatory effect of hypofractionation radiotherapy combined with PD-1 inhibitors.

17 October 2024 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
RWRong Wang
Rong Wang
GYGaofei Yin
Gaofei Yin
GWGuo Wei
Guo Wei
NLNuan Li
Nuan Li
YZYang Zhang
Yang Zhang
ZHZhi-Gang Huang
Zhi-Gang Huang
Immune system biomarkers in cancer pathogenesis offer new therapeutic avenues, as seen in cytokine (CK) profiles of laryngeal and hypopharyngeal tumors. A retrospective analysis was conducted on 58 patients with laryngeal and hypopharyngeal tumors and 27 patients with benign vocal cord lesions to explore the role of serum CKs in these diseases’ characteristics and immunotherapy. The differences in the levels of 12 cytokines were measured. Additionally, the study examined the correlation between T helper cells (Th)1/Th2 cytokine levels and the clinical characteristics and immunotherapy efficacy of laryngeal and hypopharyngeal cancers. The results show that the balance of Th1/Th2 is biased towards Th2 in patients with laryngeal and hypopharyngeal tumors. Among these, interleukin (IL)-6 (P = 0.021) was highly expressed in laryngeal tumors, and the expression levels of IL-1β (P = 0.008), IL-6 (P = 0.005), and IL-8 (P = 0.05) were higher in patients with poorly differentiated laryngeal tumors. The level of IL-4 (P = 0.0048) was significantly correlated with tumor location. The expression levels of IL-2 (P = 0.010), IL-4 (P = 0.028), IL-10 (P = 0.011), IL-12p70 (P = 0.034), IL-17 (P = 0.024), tumor necrosis factor (TNF)-α (P = 0.003), and interferon (IFN)-γ (P = 0.007) were related to lymph node metastasis. The level of IFN-γ (P = 0.016) was correlated with the efficacy of neoadjuvant therapy, while the level of IFN-α (P = 0.013) was significantly correlated with programmed death ligand 1 (PD-L1) expression. The Principal Component Analysis (PCA) results showed that patients with tumors, poor differentiation, and lymph node metastasis had higher levels of Th1 and Th2 cytokine separation. In conclusion, the shift in the balance of Th1 and Th2 cytokine expression indicates higher tumor invasiveness, and IFN has potential as a circulating molecular marker for immunotherapy of head and neck squamous cell carcinoma.

25 February 2025 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
GYGaofei Yin
Gaofei Yin
NLNuan Li
Nuan Li
XCXiaohong Chen
Xiaohong Chen
YZYang Zhang
Yang Zhang
ZHZhi-Gang Huang
Zhi-Gang Huang
GWGuo Wei
Guo Wei
Objective Hypopharyngeal squamous cell carcinoma (HSCC) is a highly malignant tumor type in the head and neck region. In recent years, neoadjuvant therapy has significantly improved the laryngeal preservation rate among patients. However, there are variations in the efficacy of neoadjuvant therapy, and the identification of reliable predictive biomarkers for its efficacy remains a challenging research focus. This study aims to explore the correlation between the expression of P53, P16, and Ki67 and the response to neoadjuvant therapy. Methods A retrospective analysis was conducted on 120 patients who underwent neoadjuvant therapy at Beijing Tongren Hospital, Capital Medical University, from January 2021 to June 2024. Patients were grouped based on their treatment response and the type of neoadjuvant therapy received. Group analysis were employed to assess the predictive value of P53, P16, and Ki67 for treatment efficacy across different neoadjuvant therapy groups. Results A total of 120 patients were included in the study, with 60 patients each in the good response and poor response groups. The study comprised three neoadjuvant therapy groups: neoadjuvant chemotherapy, neoadjuvant targeted therapy combined with chemotherapy, and neoadjuvant immunotherapy combined with chemotherapy. Each group had 20 patients with good and poor responses, respectively. Among patients with P53 positivity, the effective rate after neoadjuvant therapy was 35.94%, significantly lower than the 66.07% observed in P53negative patients (p = 0.0017). For P16 positivity, the effective rate was 28.57%, lower than the 52.83% in P16negative patients (p = 0.0880). For patients with Ki67 < 60%, the effective rate was 33.33%, significantly lower than the 66.67% in those with Ki67 ≥ 60% (p = 0.0005). Comprehensively evaluate confirmed that P53 positivity and Ki67 < 60% were associated with poor response to neoadjuvant therapy, while P53 negativity and Ki67 ≥ 60% were associated with good response. Conclusion Our findings suggest that the combination of P53 and P16 can be used as a preliminary tool to assess the efficacy of neoadjuvant therapy in patients with HSCC. Specifically, patients with P53 positivity and Ki67 < 60% tend to have lower sensitivity to neoadjuvant therapy. Further research may be needed to clarify the precise role of P16 in HSCC.

20 June 2026 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
LFLifei Feng
Lifei Feng
WGWen Gao
Wen Gao
GYGaofei Yin
Gaofei Yin
QZQi Zhong
Qi Zhong
XCXiaohong Chen
Xiaohong Chen
YZYang Zhang
Yang Zhang

9 February 2026 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
LFLifei Feng
Lifei Feng
GYGaofei Yin
Gaofei Yin
WGWen Gao
Wen Gao
JFJugao Fang
Jugao Fang
QZQi Zhong
Qi Zhong
YZYang Zhang
Yang Zhang
Head and neck cancers (HNCs) are common malignancies with generally unfavorable prognoses worldwide, among which squamous cell carcinoma (SCC) represents t